IFITM3 and bladder transitional cell carcinoma: In addition, high IFITM3 expression could be used to identify an inflamed TME and immuno-hot tumors in BLCA, and IFITM3 had the potential to predict the molecular subtype and therapeutic efficacy of various therapies in BLCA.